Aktuellt
SENASTE
The FDA approval is achieved early in Q1, probably roughly a month later than initially expected. The approval is positive, and the US launch will contribute to improved growth during 2022. The FDA approval will also allow XVIVO to show that the company can deliver sales synergies based on the Organ assist acquisition.
LÄS MER
